Cholecystokinin Octapeptide Ammonium: Atomic Facts, Mechanisms, and Research Applications

Executive Summary: Cholecystokinin octapeptide ammonium (CCK-8 ammonium, CAS 70706-98-8) is a sulfated, brain–gut peptide that acts as a potent agonist at CCK1R and CCK2R G protein-coupled receptors, initiating β-arrestin 2, p38 MAPK, Akt, NOX4, PGC-1α, and PPARα/γ signaling cascades (Han et al., 1986; APExBIO). It modulates anxiety-like behavior, morphine withdrawal symptoms, neuronal apoptosis, immune response, and atrial natriuretic peptide (ANP) secretion. Its biological effects are context- and concentration-dependent, with active ranges of 0.01–1 μmol/L in vitro and 1–10 pmol/g body weight in vivo. Sulfation is essential for activity, distinguishing it from desulfated analogs. Product C8717 from APExBIO is optimized for research, requiring storage at -20°C under nitrogen and immediate use after solution preparation.

Biological Rationale

Cholecystokinin octapeptide ammonium (CCK-8 ammonium) is a synthetic, sulfated peptide analog of endogenous CCK-8, a prominent member of the brain-gut peptide family. It is present in both the central nervous system and the gastrointestinal tract, where it regulates digestion, satiety, and a spectrum of neuronal functions (Han et al., 1986). CCK-8 ammonium is designed for in vitro and in vivo studies that require a stable, highly active form of CCK for receptor-specific investigations. The sulfation at the tyrosine residue is essential for high-affinity receptor binding and functional activity. The peptide’s pleiotropic effects make it a central tool for dissecting neuroimmune, behavioral, and metabolic pathways.

Mechanism of Action of Cholecystokinin octapeptide ammonium

CCK-8 ammonium primarily exerts its effects via activation of two G protein–coupled receptors: CCK1R (predominant in peripheral tissues and certain brain regions) and CCK2R (widespread in the CNS). Upon binding, it triggers downstream intracellular cascades, including:

• β-arrestin 2–mediated signaling—modulates receptor internalization and non-canonical signaling.
• p38 MAPK and Akt pathway activation—regulates apoptosis, cell survival, and stress responses.
• NOX4, PGC-1α, and PPARα/γ signaling—essential for metabolic regulation and ANP secretion in cardiac tissue (see detailed pathway review).

These pathways underlie the compound’s ability to attenuate morphine withdrawal-induced anxiety, inhibit neuronal apoptosis, modulate immune responses, and induce ANP release. Sulfation is mandatory—desulfated CCK-8 fails to bind with sufficient affinity or trigger receptor-mediated effects (Han et al., 1986).

Evidence & Benchmarks

• CCK-8 ammonium (0.25–4 ng, i.c.v. or i.th.) dose-dependently antagonizes electroacupuncture (EA) and morphine analgesia in rats, with effects lasting at least 4 hours (Han et al., 1986).
• CCK-8 administration does not alter baseline nociception, indicating specific antagonism of opioid pathways (Han et al., 1986, DOI).
• Antiserum against CCK-8 reverses EA and morphine tolerance, confirming endogenous CCK-8’s role as an anti-opioid substrate (DOI).
• Desulfated CCK-8 analogs are inactive in these paradigms, underscoring the necessity of the sulfate group (DOI).
• Effective in vitro concentrations: 0.01–1 μmol/L; in vivo: 1–10 pmol/g body weight, as validated in behavioral and tissue assays (APExBIO).

This extends prior scenario-based evaluations (see practical laboratory scenarios) by detailing atomic, peer-reviewed dose-response data and receptor specificity.

Applications, Limits & Misconceptions

Cholecystokinin octapeptide ammonium is used in:

• Anxiety-like behavior models—notably in zebrafish and rodents, for quantifying anxiolytic or anxiogenic effects.
• Morphine withdrawal anxiety attenuation—in vivo, to elucidate anti-opioid mechanisms.
• In vitro apoptosis inhibition—CCK2R-dependent reduction of neuronal apoptosis.
• Immune response modulation—regulation of cytokine production in immune cells.
• Cardiometabolic research—stimulation of ANP secretion via NOX4–PGC-1α–PPAR signaling (mechanistic extension).

These functions make CCK-8 ammonium a versatile experimental tool. This article clarifies the molecular determinants of efficacy, supplementing workflow troubleshooting guides (see workflow integration).

Common Pitfalls or Misconceptions

• Desulfated CCK-8 analogs are functionally inactive at CCK1R/CCK2R (DOI).
• CCK-8 ammonium is insoluble in DMSO, ethanol, and water; improper dissolution impairs assay results (APExBIO).
• Solutions degrade rapidly; long-term storage in solution is not recommended.
• High concentrations can produce off-target effects, including paradoxical analgesia or non-specific toxicity (DOI).
• Baseline nociception and non-opioid analgesia (e.g., 5-HT, NE pathways) are unaffected by CCK-8 (DOI).

Workflow Integration & Parameters

For optimal results with Cholecystokinin octapeptide ammonium (C8717) from APExBIO:

• Storage: -20°C, dry, sealed, under nitrogen, protected from light.
• Dissolution: Insoluble in DMSO, ethanol, and water; use compatible buffers as per product sheet.
• Concentration: For in vitro studies, use 0.01–1 μmol/L; for in vivo, 1–10 pmol/g body weight.
• Application: Prepare solutions immediately before use. Do not store prepared solutions.
• Controls: Always include desulfated CCK-8 as a negative control.

Integration into neurobiological and immunological workflows is detailed in this troubleshooting guide, which this article updates with atomic mechanistic claims and quantitative parameters.

Conclusion & Outlook

Cholecystokinin octapeptide ammonium (CCK-8 ammonium) is a rigorously validated, sulfated peptide tool for dissecting CCK1R/CCK2R-mediated signaling, neuronal apoptosis, immune modulation, and opioid pathway antagonism. Its reproducibility and atomic mechanism-of-action claims are underpinned by benchmarks spanning behavioral, cellular, and molecular domains. APExBIO’s C8717 product delivers defined, high-purity peptide, facilitating robust experimental outcomes when protocol boundaries are respected. Ongoing research is expanding the translational scope of sulfated CCK-8, with emerging applications in neurodegenerative, cardiometabolic, and behavioral disease models (see pathway insights).